Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine.
Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine.
复制标题
口服(14C)氨基比林后通过呼吸分析定量评估肝功能。
DOI：
10.7326/0003-4819-83-5-632
复制
发表时间：
1975
影响因子：
39.2
通讯作者：
E. Vesell
中科院分区：
文献类型：
--
作者：
G. Hepner;E. Vesell
二甲氨基安替比林（氨基吡啶）的肝脏代谢率主要通过n -去甲基化发生，在口服微量剂量[14C]氨基吡啶2小时后，通过测量呼吸样本中排出的14CO2的比活性来评估。对照组患者2小时内14C随14CO2排出的百分比为7.0 +/- 1.3 (SD)%，门静脉肝硬化（2.6 +/- 1.2%）、脂肪肝（4.7 +/- 1.1%）、肝炎（2.6 +/- 1.4%）和肝恶性肿瘤（3.5 +/- 1.8%）患者的14C排泄百分比显著低于对照组（P < 0.01）。在24例非恶性疾病引起的胆汁淤积患者中，16例平均14CO2排泄正常。门脉肝硬化患者14CO2排泄与氨基吡啶代谢清除率（r = 0.92）、血清白蛋白（r = 0.75）、溴磺胺保留率（r = 0.73）高度相关。当肝炎消退时，异常的14CO2排泄恢复正常。提示氨比林呼气试验是一种安全、简便、定性、定量的肝功能检测方法。
The rate of hepatic metabolism of dimethylaminoantipyrine (aminopyrine), which occurs primarily through N-demethylation, was assessed by measurement of the specific activity of 14CO2 excreted in breath samples obtained 2 hours after oral administration of a trace dose of [14C]aminopyrine. The percentage of administered 14C excreted in 14CO2 in 2 hours was 7.0 +/- 1.3 (SD)% in control patients, and significantly less (P less than 0.01) in patients with portal cirrhosis (2.6 +/- 1.2%), fatty liver (4.7 +/- 1.1%), hepatitis (2.6 +/- 1.4%), and hepatic malignancy (3.5 +/- 1.8%). In 16 of 24 subjects with cholestasis not caused by malignant disease the mean 14CO2 excretion was normal. The 14CO2 excretion in patients with portal cirrhosis correlated highly with aminopyrine metabolic clearance rate (r equals 0.92), serum albumin (r equals 0.75), and retention of bromsulphalein (r equals 0.73). Abnormal 14CO2 excretion returned to normal in patients with hepatitis, when the hepatitis resolved. The data suggest that the aminopyrine breath test is a safe, simple, qualitative and quantitative liver function test.